Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy

Clinical Infectious Diseases

Volumn 30, Issue 3, 2000, Pages 504-510

  Huang, Susan S ^b   Barbour, Jason D ^a   Deeks, Steven G ^b   Huang, Jeannie S ^a   Grant, Robert M ^a   Ng, Valerie L ^c   McCune, Joseph M ^a  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE;

ADULT; AGED; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0005248351     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313714     Document Type: Article

References (35)

1. 1. McCune JM, Hellerstein M. T cell turnover in HIV-1 disease. Immunity 1997;7:583-9.
2. 2. Moses A, Nelson J, Bagby G. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998;91:1479-95.
3. 3. McCune JM, Kaneshima H. The hematopathology of HIV-1 disease: experimental analysis in vivo. In: Roncarolo M-G, Namikawa R, Peault B, eds. Human hematopoiesis in SCID mice. Austin, TX: R. G. Landes, 1995:129-56.
4. 4. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled study. N Engl J Med 1987;317:192-7.
5. 5. Schacter LP, Rozencweig M, Beltangady M, et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 1992;80:2969-76.
6. 6. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995;171(Suppl 2):S131-9.
7. 7. Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1340-5.
8. 8. Nielsen SD, Ersboll AK, Mathiesen L, Nielsen JO, Hansen JES. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus infected patients. J Infect Dis 1998;178: 1299-305.
9. +lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-8.
10. 10. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999;5:83-9.
11. +T cell response after virologic failure of protease inhibitor based regimens: correlation between CD4 and viral load response after two years of therapy [abstract 494]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
12. 12. Molina JM, Scadden DT, Sakaguchi M. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990;76:2476-82.
13. 13. Davis BR, Schwartz DH, Marx JC, et al. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 1991;65:1985-90.
14. 14. Monté D, Groux H, Raharinivo B, et al. Productive human immunodeficiency virus-1 infection of megakaryocytic cells is enhanced by tumor necrosis factor-α. Blood 1992;79:2670-9.
15. 15. Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF. Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med 1989;169:327-32.
16. 16. Su L, Kaneshima H, Bonyhadi M, et al. HIV-1 induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo. Immunity 1995;2:25-36.
17. +hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 is mediated by endogenous transforming growth factor-β1. J Exp Med 1996;183:99-108.
18. 18. Chirmule M, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev 1996;60:386-406.
19. 19. Sun NC, Shapshak P, Lachant NA, et al. Bone marrow examination in patients with AIDS and AIDS-related complex (ARC): morphologic and in situ hybridization studies. Am J Clin Pathol 1989;92:589-94.
20. 20. Moses AV, Williams S, Heneveld ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal he-matopoietic growth factors. Res Virol 1990;141:195-200.
21. 21. Stutte HJ, Muller H, Folk S. Pathophysiological mechanisms of HIV-induced defects in haematopoiesis: pathology of the bone marrow. Res Virol 1990;141:195-200.
22. 22. Stanley SK, McCune JM, Kaneshima H, et al. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med 1993;178:1151-63.
23. 23. Bahner I, Kearns K, Coutinho S, Leonard EH, Kohn DB. Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-I-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997;90:1787-98.
24. 24. Potts BJ, Hoggan MD, Lamperth L, Spivak J. Replication of HIV-1 and HIV-2 in human bone marrow cultures. Virology 1992;188:840-9.
25. +hematopoietic progenitor cells. Blood 1990;75:2292-8.
26. 26. Esser R, Glienke W, von Briesen H, Rübsamen-Waigmann H, Andreesen R. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 1996;88:3474-81.
27. 27. Lahdevirta J, Mauray CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
28. 28. Merrill JE, Koyanagi Y, Chen ISY. Interleukin-1 and tumor necrosis factor-α can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989;63:4404-8.
29. 29. Von Sydow M, Sonnerborg A, Gaines H. Interferon-alpha and tumor necrosis factor-α in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991;7:375-80.
30. 30. Fuchs D, Hausen A, Reibnegger G, et al. Interferon-γ concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 1989;2:158-62.
31. 31. Wahl SM, Allen JB, McCartney FN. Macrophage-and astrocyte-derived transforming growth factor-β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 1991; 173:981-91.
32. 32. Kekow J, Wachsman W, McCutchan JA. Transforming growth factor-β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990;87:8321-5.
33. 33. Geissler RG, Ottmann OG, Kojouharoff G. Influence of human recombinant interferon α and interferon-γ on bone marrow progenitor cells of HIV-positive individuals. AIDS Res Hum Retroviruses 1992;8:521-5.
34. 34. Zauli G, Davis BR, Re MC. Tat protein stimulates production of transforming growth factor-β1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1 -induced hematopoietic suppression. Blood 1992;80:3036-43.
35. 35. Buonaguro L, Barillari G, Chang HK, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. Increased levels of inflammatory cytokines, including tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6, have been detected in specimens from human immunodeficiency virus type 1 (HIV-1)-infected individuals. J Virol 1992;66:7159-67.